Gerard Honig

Symbiotic Health, Goddard Labs eye Brooklyn move

By GREGORY ZELLER // Two of Long Island’s most-promising biotech startups are packing up their R&D and heading for greener pastures. At least for now. Symbiotic Health and Goddard Labs – both jointly funded by regional business booster Accelerate Long Island and the venture-backed Long Island Emerging Technologies Fund – are gearing up to move to Brooklyn, where affordable, short-term lab space is readily available. Spun out of the Feinstein Institute for Medical Research, Symbiotic…


Symbiotoc Health CEO Gerard Honig

Symbiotic Health gets $100K in funding

By GREGORY ZELLER // A spinoff of the Feinstein Institute for Medical Research has snagged a critical $100,000 stake from Accelerate Long Island and the Long Island Emerging Technologies Fund – good news for anyone suffering from the most prevalent hospital-based infection in the United States. Symbiotic Health, which does battle against the insidious Clostridium difficile infection, announced today that Accelerate Long Island has matched the $50,000 investment the LIETF fund made in June –…


Symbiotoc Health CEO Gerard Honig

Leading the fight against C. Diff

By GREGORY ZELLER // Researchers battling the insidious clostridium difficile infection are making progress on several new fronts, including a novel “poop pill” developed by Symbiotic Health, a spinoff from North Shore-LIJ’s Feinstein Institute. C. Diff, as it is known, is the most prevalent hospital-acquired infection in the United States and “an immediate public health threat,” according to the Centers for Disease Control. The infection attacks the gastrointestinal tract when broad-spectrum antibiotics fight off infections but…